During the recent session, Dyne Therapeutics Inc (NASDAQ:DYN)’s traded shares were 0.42 million, with the beta value of the company hitting 1.07. At the last check today, the stock’s price was $13.99, reflecting an intraday loss of -0.85% or -$0.12. The company’s market capitalization is $1.42B, and the average intraday trading volume over the past 10 days was 3.08 million shares, and the average trade volume was 1.32 million shares over the past three months.
Dyne Therapeutics Inc (DYN) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.25. DYN has a Sell rating from 0 analyst(s) out of 8 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 1 suggest Overweight, and 7 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -0.91.
Dyne Therapeutics Inc (NASDAQ:DYN) trade information
Dyne Therapeutics Inc (DYN) registered a -0.85% downside in the last session and has traded in the red over the past 5 sessions. The stock plummet -0.85% in intraday trading to $13.99, hitting a weekly high. The stock’s 5-day price performance is -9.97%, and it has moved by -42.43% in 30 days. Based on these gigs, the overall price performance for the year is -13.59%. The short interest in Dyne Therapeutics Inc (NASDAQ:DYN) is 10.52 million shares and it means that shorts have 12.33 day(s) to cover.
The consensus price target of analysts on Wall Street is $52.5, which implies an increase of 73.35% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $52 and $53 respectively. As a result, DYN is trading at a discount of -278.84% off the target high and -271.69% off the low.
Dyne Therapeutics Inc (DYN) estimates and forecasts
Statistics show that Dyne Therapeutics Inc has underperformed its competitors in share price, compared to the industry in which it operates. Dyne Therapeutics Inc (DYN) shares have gone down -68.23% during the last six months, with a year-to-date growth rate less than the industry average at 12.91% against 16.90.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings shrunk an estimated -106.26%. While earnings are projected to return 12.26% in 2025.
DYN Dividends
Dyne Therapeutics Inc is due to release its next quarterly earnings in February. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Dyne Therapeutics Inc (NASDAQ:DYN)’s Major holders
Dyne Therapeutics Inc insiders own 0.77% of total outstanding shares while institutional holders control 112.35%, with the float percentage being 113.23%. ATLAS VENTURE LIFE SCIENCE ADVISORS, LLC is the largest shareholder of the company, while 286.0 institutions own stock in it. As of 2024-06-30, the company held over 8.02 million shares (or 9.8961% of all shares), a total value of $283.03 million in shares.
The next largest institutional holding, with 7.85 million shares, is of FCPM III SERVICES B.V.’s that is approximately 9.6804% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $276.86 million.
Also, the Mutual Funds coming in first place with the largest holdings of Dyne Therapeutics Inc (DYN) shares are Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF. Data provided on Sep 30, 2024 indicates that Vanguard Total Stock Market Index Fund owns about 2.65 shares. This amounts to just over 2.61 percent of the company’s overall shares, with a $37.07 million market value. The same data shows that the other fund manager holds slightly less at 2.09, or about 2.05% of the stock, which is worth about $29.12 million.
